ArticleCancers2026
Twelve-Month Metastatic State as a Landmark-Based Prognostic Stratifier in Metastatic Sarcoma.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrognostic assessment in metastatic sarcoma remains challenging, and baseline variables may not adequately reflect outcome after metastatic onset. We investigated whether the 12-month landmark provides clinically relevant prognostic stratification for post-metastasis survival, while institution was examined as a contextual and adjustment variable rather than as the primary analytic focus.
methodsThis retrospective observational study was based on prospectively collected real-world-time clinical data from two sarcoma centers. Overall survival (OS) and post-metastasis survival (PMS) were first analyzed descriptively across the two contributing centers using Kaplan-Meier methods. The principal analysis was a landmark-based prognostic stratification of PMS from 12 months after first metastatic documentation, with patients classified at the landmark as oligometastatic or polymetastatic. Univariable and multivariable Cox regression models were used to assess prognostic associations.
resultsA total of 236 patients were included (135 at Institution A and 101 at Institution B). Crude OS was broadly comparable between institutions, whereas PMS showed a numerical separation. In the landmark analysis, metastatic state at 12 months clearly stratified subsequent PMS, with persistent oligometastatic disease associated with more favorable outcome than polymetastatic disease. In the reduced multivariable landmark model, polymetastatic state at 12 months remained the strongest independent predictor of inferior PMS (HR 3.09, 95% CI 1.87-5.09;
conclusionsIn metastatic sarcoma, realized metastatic state at 12 months provides stronger landmark-based prognostic stratification for post-metastasis survival than crude institutional comparison. These findings support a longitudinal state-based prognostic framework in which survival after metastatic onset is more informatively stratified by disease state at the 12-month landmark than by crude center attribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.